A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue 5, 2009, Pages 536-540

  Petersson, Ulla ^a,b   Östgren, Carl Johan ^b   Brudin, Lars ^b   Nilsson, Peter M ^c  

^a Primary Health Care Centre   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Algorithm; Cardiovascular; Mortality; Risk; Screening

Indexed keywords

ARGININE; C REACTIVE PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ACCURACY; ADULT; ALGORITHM; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONSULTATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEIGHT; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN BLOOD LEVEL; LABORATORY; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MORTALITY; POPULATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SCREENING; SEX DIFFERENCE; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE;

EID: 72449183200     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32832b1833     Document Type: Article

References (20)

1. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10:1-10.
3. Wilhelmsen L, Wedel H, Conroy R, Fitzgerald T. Det svenska SCORE-diagrammet för kardiovaskulär risk. (The Swedish SCORE algorithm for cardiovascular risk). Läkartidningen 2004; 101:1798-1801.
4. Thomsen T. HeartScore: a new web-based approach to European cardiovascular disease risk management. Eur J Cardiovasc Prev Rehabil 2005; 12:424-426.
5. Nicholls M. Preventive cardiology in Germany: HeartScore. Circulation 2006; 114:138-139.
6. Graham IM. The importance of total cardiovascular risk assessment in clinical practice. Eur J Gen Pract 2006; 12:148-155.
7. Petersson U, Kjellstrom T. Thyroid function tests, serum lipids and gender interrelations in a middle-aged population. Scand J Prim Health Care 2001; 19:183-185.
8. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990; 36:15-19.
9. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 1991; 124:620-629.
10. Petersson U, Östgren CJ, Brudin L, Brismar K, Nilsson PM. Low Levels of insulin-like growth factor binding protein-1 (IGFBP-1) is prospectively associated with incidence of type 2 diabetes and impaired glucose tolerance (IGT). The Söderåkra Cardiovascular Risk Factor Study. Diab Metabol 2009; http://dx.doi.org/10/1016/j.diabet. 2008.11.003.
11. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303:131-137.
12. De Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 2006; 353:287-289.
13. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J Chromatogr B 2007; 851:21-29.
14. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247:2543-2546.
15. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23:2109-2123.
16. ROC curve analysis in MedCalc (2001) MedCalc software version 6.10.001, Belgium.
17. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18:1060-1061.
18. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008; 371:923-931.
19. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116.
20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.